GLP-1 receptor agonists, including drugs similar to Ozempic, have significantly impacted the management of type 2 diabetes by helping to lower blood sugar and support weight loss. However, their effectiveness varies among individuals, prompting researchers to explore the reasons behind this difference.

Eating Behaviour Influences Treatment Response

A year-long observational study in Japan involving 92 people with type 2 diabetes investigated how different eating behaviours affected responses to GLP-1 therapy. The study identified three common eating patterns linked to overeating and weight gain:

  • Emotional eating: Eating in response to negative emotions rather than hunger.
  • External eating: Overeating triggered by appealing sights or smells of food.
  • Restrained eating: Conscious limitation of food intake, which can sometimes lead to unhealthy behaviours if extreme.

Results showed that individuals who primarily overeat due to external cues—such as the attractiveness or aroma of food—experienced the most significant improvements in weight loss and blood sugar control over 12 months. In contrast, those whose overeating was mainly emotional did not see the same long-term benefits.

Implications for Personalised Treatment

Researchers suggest that GLP-1 receptor agonists may be particularly effective for people whose weight gain or elevated glucose levels are linked to external eating triggers. However, emotional eating, influenced by psychological factors, might require additional behavioural or psychological support alongside medication.

While the study found reductions in emotional and external eating behaviours at three months, emotional eating tendencies tended to return by 12 months, unlike external eating, which showed sustained improvement.

Study Limitations and Future Directions

This observational study relied partly on self-reported data and cannot definitively establish causation between eating behaviour and treatment outcomes. Participants were also highly motivated, which may have influenced results. Further large-scale or randomised controlled trials are needed to confirm these findings and explore integrating behavioural assessments into diabetes treatment planning.

Research like this highlights the complexity of weight management and diabetes care, emphasising the potential value of personalised approaches that consider individual eating behaviours.

For those interested in the science behind weight management and related therapies, Svelta Labs provides detailed educational resources and research-use products. Visit https://sveltalabs.com to learn more.

Note: This article is for educational purposes based on current research findings. It does not provide medical advice or treatment recommendations.